TransMedics (TMDX) could report better-than-expected Q4 US sales of $160.7 million if it sustains its above-average monthly organ transplant volume, Needham said in a Tuesday research report.
Based on the Scientific Registry of Transplant Recipients data, analysts said they estimate the company's average transplant volume stood at 453 for October and November, up from the average monthly volume of 394 in Q3.
The brokerage said it reiterated its buy rating on the stock with a price target of $166 per share.
Price: 128.16, Change: -1.19, Percent Change: -0.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments